

Table of Contents

1.	<u>Section 2 Exhibits</u>	1
2.	<u>2.1 Products used, Manchester, Liverpool and Sheffield V2</u>	2
3.	<u>2.2 UKHCDO Therapeutic Guidance 24.6.83</u>	14
4.	<u>2.3 UKHCDO Therapeutic Guidance December 1984</u>	16
5.	<u>2.4 Hay CRM procurement paper 2013</u>	20
6.	<u>2.5 1988 Therapeutic Guidance</u>	28
7.	<u>2.6 Figure 1 UKHCDO Annual Report 1986</u>	34
8.	<u>Section 3 Exhibits</u>	35
9.	<u>3.1 Craske Pavier Trowell bmjcred00584-0020</u>	36
10.	<u>3.2 Rizza life-expectancy bmjcred00545-0017</u>	40
11.	<u>3.3 1997 therapeutic guidelines</u>	45
12.	<u>3.4 Aledort 1985</u>	60
13.	<u>3.5 Hay 1987 blood</u>	67
14.	<u>3.6 Lancet correspondence 1985</u>	73
15.	<u>3.7 Life expectancy of Haemophilia Mejia-Carvajal et al J Thrombosis Haemostasis</u>	75
16.	<u>3.8 Farrugia Blood Transfus 2018</u>	78
17.	<u>Section 4 Exhibits</u>	88
18.	<u>4.1 GeneticLeaflet</u>	89
19.	<u>4.2 GeneticConsent</u>	96
20.	<u>4.3 Hay et al Didanosine for HIV</u>	97
21.	<u>4.4 Hay et al IL2 suppression by concentrate</u>	102
22.	<u>4.5 Hay et al High Purity VIII and HIV j.1365-2141.1998.00753.x (1)</u>	106
23.	<u>4.6 Initial letter describing rollout April 2003</u>	113
24.	<u>4.7 first DOH WP minutes</u>	115
25.	<u>4.8 Minutes DOH subgroup (procurement)</u>	119
26.	<u>4.9 tender letter to Haem Centres from Prof Hill Re Rollout 2003</u>	121
27.	<u>4.10 Letter Hill to Gutowski 31.7.03</u>	124
28.	<u>4.11 Final recombinant tender letter</u>	126
29.	<u>4.12 summary of awards</u>	129
30.	<u>4.13 Summary of Offers recombinant rollout 2003</u>	181
31.	<u>4.14 Recombinant rollout 2003-4 audit report</u>	184
32.	<u>4.15 Recombinant rollout audit report 2004-5</u>	186
33.	<u>4.16 National Procurement initial DH meeting Aug 2005</u>	204
34.	<u>4.17 Transfusion Leaflet 1990s</u>	208
35.	<div style="border: 1px dashed black; padding: 5px; display: inline-block;">GRO-B</div>	210
36.		214
37.	<u>4.20 Alprolix-Informationbooklet-1</u>	226
38.	<u>4.21 Elocta-infobookletpt</u>	244
39.	<u>4.22 Elocta-instructions</u>	256
40.	<u>4.23 Idelvion-Resource</u>	257
41.	<u>4.24 Idelvion-Instructions</u>	259

UKHCDO

- Draft – 31.07.03. (1)

Mr. Richard Gutowski
Department of Health
Skipton House
80 London Road
Elephant & Castle
London SE1 6LH.

Dear Richard,

Charles Hay, Gerry Dolan (Treasurer of UKHCDO) and myself met on 28 July 2003 to try to work out a draft plan to follow for the roll out of recombinant products for bleeding disorder patients in England.

Current Situation

(1) UKHCDO has requested information from Haemophilia Centres for all patients by P.C.T., date of birth identifier and units of Factor used. Data has been received from all but 10 small Centres and these have had written and phoned reminders and we are awaiting the data. These are all small Centres and, therefore, small numbers of patients. Once data is complete we will provide this data to the D.O.H. to be sent to the lead commissioners so that they can verify the data with the relevant P.C.T. Since we have 95% of the data we will probably provide that data we have in the next week, so that the process of verification may begin without further delay.

(2) Tenders have been received for recombinant factor VIII and IX but further consideration needs to be given to treatment of inhibitor patients.

Action required:

(1) F. Hill to draft letter to go to Centre Directors giving information about roll out, tender prices and to obtain their view on how contract should be awarded (see separate attachment). Centre Directors will be given only a short time in which to indicate their preferences so that this consultation exercise does not hold up the process unduly.

(2) D.O.H. need to provide a document to go to Commissioners, P.C.T. and Chief Executives on the roll out, indicating the funding process and the details of the roll out.

(3) Once consensus on how contract should be awarded is achieved amongst Centre Directors, this will need to be approved by D.O.H./Working Group and then it will be possible to work out the extent to which patients can have their treatment converted from plasma derived to recombinant Factor products. Draft calculations will be prepared in advance of this early September meeting and may be available by the end of this week.

(4) Obtain from Lead Commissioners which Haemophilia Centres they contract with so that D.O.H. can send them the relevant patient data. The commissioners need to verify

cont'd...

-2-

the PCT code for all patients at this stage so that roll out will then be planned completely. We need to specify a time by which this is to be completed. It is desirable that this be completed before the early September meeting of the working party

(5) Dr Hay has verified that all manufacturers are in a position to provide the volumes of recombinant factor VIII/IX likely to be involved, however we decide to award the contract and whenever the rollout starts.

Yours sincerely,

Frank G.H. Hill
Chairman – UKHCDO

Holiday plans:

Gerry Dolan	-	August 15-31
Richard Gutowski	-	August 5-20
Charles Hay	-	August 7-22, August 30-September 5
Frank Hill	-	August 23-September 7